Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of CVN424 in Healthy Volunteers
NCT03657030Phase 1Completed
- Sponsor
- Cerevance
- Start
- Sep 2018
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of solengepras in Parkinson's disease (PD) (2 arms), sponsored by Cerevance. Primary endpoints: Evaluation of adverse events, Evaluation of Hematology and 4 more. Started Sep 2018; status: completed.
02
Drugs
solengepras
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT03657030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03657030.